Beam Therapeutics (BEAM) is back in focus after a tribunal issued a binding decision on its 2019 collaboration with Prime Medicine, removing the risk of monetary damages and clarifying rights around a rare disease program.

At a share price of $36.88, Beam Therapeutics has seen a 7 day share price return of 10.16% and a 90 day share price return of 40.07%, while the 1 year total shareholder return of 71.85% contrasts with a 5 year total shareholder return that remains significantly lower. This suggests momentum has picked up recently after a weaker longer term experience for holders.

If the tribunal outcome has you looking more broadly at high growth potential in healthcare, this is a good moment to scan 40 healthcare AI stocks for other specialised opportunities.

Beam Therapeutics now has clearer legal footing and a sharp share price move, which points to a stronger story on the science and partnerships. The open question is whether the current valuation already reflects that shift.

Most Popular Narrative: 75% Undervalued

Compared with Beam Therapeutics' last close at $36.88, the most followed narrative points to a fair value of $150. That is a large gap and it rests on a detailed view of the pipeline and platform economics.

The "Molecular Pencil": Why Beam's Technology is Built to Win
The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool. By creating double-strand DNA breaks, they introduce significant risks, including unpredictable insertions, deletions, and large genomic rearrangements. Beam represents "Gene Editing 2.0". Its base editing platform is a "molecular pencil", a precision instrument that chemically rewrites a single "letter" of the genetic code without cutting the DNA backbone. This approach offers a potentially superior safety and precision profile, designed to mitigate the core risks that plague its predecessors.

Want to see what underpins that $150 figure according to davidlsander? The thesis leans on targeted revenue build ups, program level probabilities and a sizeable cash position. The tension comes from how limited the model inputs are compared with the full Beam Therapeutics pipeline, and how aggressively those core assets are framed in the long run.

Result: Fair Value of $150 (UNDERVALUED)

However, the Beam Therapeutics story still hinges on unproven clinical programs and regulatory decisions. Weaker data or delays could quickly challenge this optimistic narrative.

Another View on Beam Therapeutics' Valuation

The user narrative frames Beam Therapeutics as roughly 75% undervalued, but the market is currently assigning a very different signal through the sales multiple. At a P/S of 22.4x versus a fair ratio of 1.3x, the stock trades at a very large premium to where that ratio could move.

Even compared with the US Biotechs industry at 12.2x and similar peers at 22.5x, Beam Therapeutics is priced as if a lot has to go right. The key question is whether you view that as valuation risk or a price you are comfortable paying for the story.

Next Steps

See something in the Beam Therapeutics story that feels either too confident or too cautious? Take a closer look at the underlying data, and then pressure test both sides of the argument by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Beam Therapeutics?

If Beam Therapeutics has sharpened your interest, do not stop here. Use the Simply Wall St screener tools to surface other focused, data driven ideas.

• Target potential mispricings by checking out the 44 high quality undervalued stocks that combine quality fundamentals with promising pricing gaps.
• Prioritise resilience by scanning the 72 resilient stocks with low risk scores and focus on companies with steadier risk profiles.
• Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems before they sit on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.